| Document |
Document Title |
|
WO/2022/194905A1 |
The present invention relates to the compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2022/194976A1 |
Compounds of formula (I) are useful as LRRK2 kinase inhibitors.
|
|
WO/2022/194802A1 |
The invention relates to a compound of formula (I) wherein R1-R4 and A1 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2022/194801A1 |
The invention relates to a compound of formula (I) wherein R1-R4 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2022/189191A1 |
The invention relates to compounds of formula (I) wherein the variables are as defined in the specification. It also relates to the use of compounds of formula (I) as an agrochemical pesticide; to pesticidal mixtures comprising compounds...
|
|
WO/2022/178283A1 |
Disclosed are compounds and methods for treating tauopathy.
|
|
WO/2022/175745A1 |
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
|
|
WO/2022/171745A1 |
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing t...
|
|
WO/2022/172994A1 |
The present invention provides a method for producing an oligonucleotide having a phosphate ester bond by oxidizing an oligonucleotide precursor having a phosphite ester bond or a phosphonic acid ester bond via an oxidizing agent, wherei...
|
|
WO/2022/166749A1 |
Disclosed are a triheterocyclic compound, a preparation method therefor, and an application thereof. Specifically, provided is a triheterocyclic compound as represented by formula IA or a pharmaceutically acceptable salt thereof. The tri...
|
|
WO/2022/166991A1 |
An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.
|
|
WO/2022/167002A1 |
Disclosed is a 1,4-sulfobridged polycyclic compound containing a dihydrobenzofuran structure, belonging to the field of organic synthesis, and having a structure as shown in formula (I). Further disclosed is a preparation method therefor...
|
|
WO/2022/159746A1 |
Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).
|
|
WO/2022/157166A1 |
The present invention relates to a group of compounds of formula (I) which are inhibitors of the Discoidin Domain Receptors (DDR1/2), whose overexpression is produced in several diseases such as cancer, pulmonary fibrosis, cirrhotic live...
|
|
WO/2022/159436A1 |
Provided is a compound, including a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein W is a direct bond or an optionally substituted C, and if W is a direct bond, then X1, X2, X3, and X4 are each independentl...
|
|
WO/2022/152316A1 |
A biphenyl derivative, a preparation method therefor and the use thereof in the preparation of a medicine for treating related diseases. In particular, the present application relates to a compound represented by formula (I) and a pharma...
|
|
WO/2022/150920A1 |
The present application relates to the treatment of plant nematode infections. For example, the application relates to the use of one or more compounds of Formula (I) as defined herein, or compositions comprising these compounds, for tre...
|
|
WO/2022/150316A1 |
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
|
|
WO/2022/150574A1 |
Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
|
|
WO/2022/148434A1 |
Provided are a class of pyridone multiple-membered ring derivatives and the use thereof. Specifically provided are a compound as represented by formula (VI) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/147302A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/135572A1 |
A compound represented by general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparation method ther...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/138833A1 |
The present invention provides a photoelectric conversion element which is reduced in the electric field intensity dependency of a photoelectric conversion efficiency. The present invention also provides an imaging element, an optical se...
|
|
WO/2022/140527A1 |
The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
|
|
WO/2022/140144A1 |
Disclosed are various synthetic methods to prepare structural analogs of largazole and derivatives thereof. One structural analog is an amide isostere of largazole. Another structural analog replaces the thiazole ring of largazole with a...
|
|
WO/2022/136509A1 |
The disclosure is directed to compounds of formula (I),and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2022/139249A1 |
The present invention relates to a polysubstituted imidazole[4,5-c][1,2]thiazine derivative and a use of an agent comprising same as an active agent, which is useful for infectious diseases associated with vascular inflammation caused by...
|
|
WO/2022/131869A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2022/130238A1 |
A new process for the synthesis of amide derivatives of 8-hydroxypenicillanic acid is described, more specifically starting from amide derivatives of the 6-aminopenicillanic nucleus protected as tert-butylcarbamate.
|
|
WO/2022/131757A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2022/133345A1 |
Compounds with KRAS G12C inhibitory activity are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation. Preferably the compounds fall within formula (I).
|
|
WO/2022/129331A1 |
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseas...
|
|
WO/2022/133064A1 |
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions th...
|
|
WO/2022/125849A1 |
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).
|
|
WO/2022/117473A1 |
The present invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/115400A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound IA, wherein R1 is described herein. Compound IA can be useful in sy...
|
|
WO/2022/105930A1 |
The present disclosure provides compounds of Formula (I) a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof, for use in, e.g. treating a condition, disease or disorder in which increased (e.g., excessive) STING act...
|
|
WO/2022/109573A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...
|
|
WO/2022/108354A1 |
The present invention provides a novel compound, a solvate thereof, a hydrate thereof, a prodrug thereof, an isomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an antibiotic composition compri...
|
|
WO/2022/106469A2 |
The present invention provides compounds of formula (I) which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.
|
|
WO/2022/100717A1 |
Disclosed are a leukocyte classification reagent and kit, a classification method, an erythrocyte analysis reagent and kit, and an analysis method. Both the leukocyte classification reagent and the erythrocyte analysis reagent comprise a...
|
|
WO/2022/100727A1 |
The present invention provides a novel class of imidazothiazole compounds as ATX (Autotaxin) inhibitors, a pharmaceutical composition comprising the compound, and a use of the compound and the composition to treat a mammal suffering from...
|
|
WO/2022/099659A1 |
Provided are a leukocyte classification reagent, reagent kit, and classification method, and an erythrocyte analysis reagent, reagent kit, and analysis method. Each of the leukocyte sorting reagent and the erythrocyte analysis reagent co...
|
|
WO/2022/089296A1 |
Disclosed are a thienopyrimidine compound, a pharmaceutical composition comprising same, and an application thereof. The thienopyrimidine compound has a structure represented by formula I. The compound interferes with the interaction bet...
|
|
WO/2022/093856A1 |
The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain ...
|
|
WO/2022/078971A1 |
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregat...
|
|
WO/2022/078350A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
|
|
WO/2022/079290A2 |
The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target pro...
|
|
WO/2022/076796A1 |
The present disclosure provides novel macrocyclic peptides which inhibit the PD- 1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
|
